Medical therapy for rheumatic heart disease: is it time to be proactive rather than reactive?
Rheumatic Heart Disease (RHD) is well known to be an active inflammatory process which develops progressive calcification and leaflet thickening over time. The potential for statin therapy in slowing the progression of valvular heart disease is still controversial. Retrospective studies have shown that medical therapy is beneficial for patients with calcific aortic stenosis and recently for rheumatic valve disease. However, the prospective randomized clinical trials have been negative to date. This article discusses the epidemiologic risk factors, basic science, retrospective and prospective studies in valvular heart disease and a future clinical trial to target RHD with statin therapy to slow the progression of this disease. Recent epidemiological studies have revealed the risk factors associated with valvular disease include male gender, smoking, hypertension and elevated serum cholesterol and are similar to the risk factors for vascular atherosclerosis. An increasing number of models of experimental hypercholesterolemia demonstrate features of atherosclerosis in the aortic valve (AV), which are similar to the early stages of vascular atherosclerotic lesions. Calcification, the end stage process of the disease, must be understood as a prognostic indicator in the modification of this cellular process before it is too late. This is important in calcific aortic stenosis as well as in rheumatic valve disease. There are a growing number of studies that describe similar pathophysiologic molecular markers in the development of rheumatic valve disease as in calcific aortic stenosis. In summary, these findings suggest that medical therapies may have a potential role in patients in the early stages of this disease process to slow the progression of RHD affecting the valves. This review will summarize the potential for statin therapy for this patient population.
Rajamannan
Nalini M
NM
Bluhm Cardiovascular Institute, Nortwestern University Feinberg School of Medicine, Tarry, Chicago IL, USA. n-rajamannan@northwestern.edu
Antonini-Canterin
Francesco
F
Moura
Luis
L
Zamorano
Jose L
JL
Rosenhek
Raphael A
RA
Best
Patricia Jm
PJ
Lloyd
Margaret A
MA
Rocha-Goncalves
F
F
Chandra
Sarat
S
Alfieri
Ottavio
O
Lancellotti
Patrizio
P
Tornos
Pilar
P
Baliga
Ragavendra R
RR
Wang
Andrew
A
Bashore
Thomas
T
Ramakrishnan
S
S
Spargias
Konstantinos
K
Shuvy
Mony
M
Beeri
Ronen
R
Lotan
Chaim
C
Suwaidi
Jassim Al
JA
Bahl
Vinay
V
Pierard
Luc A
LA
Maurer
Gerald
G
Nicolosi
Gian Luigi
GL
Rahimtoola
Shahbudin H
SH
Chopra
K
K
Pandian
Natesa G
NG
D000818:Animals; D001024:Aortic Valve Stenosis / Q000453:epidemiology / Q000517:prevention & control*; D015984:Causality; D015897:Comorbidity; D006801:Humans; D008946:Mitral Valve Stenosis / Q000453:epidemiology / Q000517:prevention & control*; D012214:Rheumatic Heart Disease / Q000453:epidemiology / Q000517:prevention & control*; D012307:Risk Factors